Migraine is the third most common disease in the world

with an estimated global prevalence of 14.7%

that’s around 1 in 7 people

Drug repurposing to treat migraine

Using the target identification and validation platform, Geneware has identified an approved drug with the ability to interfere with a recently uncovered pain signaling pathway that’s involved in migraine. This follows a similar development path that Viagra and Botox had been repurposed for different indications. This could potentially save millions in cost and years in time to bring a product to market for migraine. Geneware is now in partnership with a pharma company to further develop it.